Addex spin-out Neurosterix closes $105M Series B to fund Phase 2 of schizophrenia drug NTX-253

Neurosterix, the 2024 spin-out of Addex Therapeutics, closed a $105 million Series B round from life science investors, announced on November 11, 2026. Proceeds will mainly fund Phase 2 development of NTX-253, an oral M4 positive allosteric modulator for schizophrenia, and the company's wider neuropsychiatric pipeline. Addex did not take part, and its stake is now 8.5%, valued at $18.6 million.

12 Nov 2026 · Addex Therapeutics Ltd. ADXN · Company news

Company's press release (SEC filing): Addex Therapeutics Ltd. ↗

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More FinancingAll →

Financing

Addex spin-out Neurosterix closes $105M Series B to fund Phase 2 of schizophrenia drug NTX-253

IM Cannabis reports C$13.9M nine-month net loss as revenue slides to C$9.0M

Femasys Q3 2026: $30M private placement closed; U.S. sales flat, total sales fall 44.5% to $404,597

Mingteng International, an automotive mold maker, prices $2.00/share registered direct offering with pre-funded warrants

Organigram to acquire Aurora Cannabis for about C$561M, backed by BAT private placement and ATB credit facilities

Windward Bio prices Nasdaq IPO of 10.3 million shares at $17, targeting $225 million in gross proceeds

Lichen International prices $3.5M registered direct offering of units with warrants on Nasdaq